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Background: The sigma-2 receptor is an attractive target for tumor imaging and targeted therapy 
because it is overexpressed in multiple types of solid tumors, including prostate cancer, breast 
cancer, and lung cancer. SV119 is a synthetic small molecule that binds to sigma-2 receptors 
with high affinity and specificity. This study investigates the utility of SV119 in mediating the 
selective targeting of liposomal vectors in various types of cancer cells.
Methods: SV119 was covalently linked with polyethylene glycol-dioleyl amido aspartic acid 
conjugate (PEG-DOA) to generate a novel functional lipid, SV119-PEG-DOA. This lipid 
was utilized for the preparation of targeted liposomes to enhance their uptake by cancer cells. 
Liposomes with various SV119 densities (0, 1, 3, and 5 mole%) were prepared and their cellular 
uptake was investigated in several tumor cell lines. In addition, doxorubicin (DOX) was loaded 
into the targeted and unmodified liposomes, and the cytotoxic effect on the DU-145 cells was 
evaluated by MTT assay.
Results: Liposomes with or without SV119-PEG-DOA both have a mean diameter of 
approximately 90 nm and a neutral charge. The incorporation of SV119-PEG-DOA significantly 
increased the cellular uptake of liposomes by the DU-145, PC-3, A549, 201T, and MCF-7 
tumor cells, which was shown by fluorescence microscopy and the quantitative measurement 
of fluorescence intensity. In contrast, the incorporation of SV119 did not increase the uptake of 
liposomes by the normal BEAS-2B cells. In a time course study, the uptake of SV119 liposomes 
by DU-145 cells was also significantly higher at each time point compared to the unmodified 
liposomes. Furthermore, the DOX-loaded SV119 liposomes showed significantly higher 
cytotoxicity to DU-145 cells compared to the DOX-loaded unmodified liposomes.
Conclusion: SV119 liposomes were developed for targeted drug delivery to cancer cells. 
The targeting efficiency and specificity of SV119 liposomes to cancer cells was demonstrated 
in vitro. The results of this study suggest that SV119-modified liposomes might be a promising 
drug carrier for tumor-targeted delivery.
Keywords: SV119, targeted delivery, liposomes, cellular uptake, cancer therapy
Introduction
One major problem with conventional anticancer agents is their severe side effects on 
normal tissues and organs. To solve this issue, targeted drug delivery to solid tumors 
was developed as an effective strategy to improve the therapeutic effect and minimize 
toxicity. Many factors affect the success rate of targeted drug delivery, including the 
choice of targeting ligands. Many types of ligands have been explored, including 
antibodies, peptides, aptamers, and small molecule ligands.1 Small molecule ligands 
have the advantages of minimal immunogenicity, excellent chemical stability, and ease 
of synthesis.2 Some examples of small molecule ligands that have been developed for 
Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
4473
O R I G I N A L  R E S E A R C H
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/IJN.S31981
International Journal of Nanomedicine 2012:7
tumor targeting include ligands of the folate receptor,3 prostate-
specific membrane antigen (PSMA),4 and integrin receptors.5 
There has been a recent interest in exploring sigma receptor 
ligands for tumor imaging and targeted therapy. Sigma receptors 
are overexpressed in a variety of human tumors including 
non-small cell lung carcinoma (NSCLC), prostate cancer, 
melanoma, and breast cancer.6–8 The small molecule ligands 
of sigma receptors are considered potential tumor imaging 
agents.6–8 The authors of this study and Dr Huang’s group 
have reported that sigma receptor ligands, such as anisamide, 
effectively mediate the selective delivery of liposomes 
containing doxorubicin (DOX) to prostate cancer cells in vitro 
and in vivo.9,10 Extensive studies by Dr Huang’s group have 
demonstrated the targeted delivery of oligodeoxynucleotides 
and siRNA to lung cancer and melanoma using anisamide-
decorated nanoparticles.11–13 Another sigma receptor ligand, 
haloperidol, was shown to improve the transfection of MCF-7 
breast carcinoma cells by more than 10-fold, compared with 
the control (unmodified) liposomes.14
Neither anisamide nor haloperidol distinguishes between 
the sigma-1 or sigma-2 receptor subtypes with respect to 
binding. This study determines whether sigma 2-selective 
ligands can be employed for the targeted delivery of liposomal 
vectors. There are several potential advantages associated with 
sigma 2-selective ligands for tumor-targeted delivery. First, 
there is a higher density of sigma-2 versus sigma-1 receptors 
in tumor samples and cultured tumor cells.15–17 Second, ligand 
binding and photoaffinity labeling studies have demonstrated 
a lower expression of sigma-2 versus sigma-1 receptors in 
normal tissues from the central nervous system, gastrointestinal 
tract, kidney, liver, and heart.18 Third, a correlation between 
sigma-2 receptor expression and tumor proliferation has been 
established both in vitro and in vivo,19,20 but no such correlation 
was observed for the sigma-1 subtype.
SV119 is a small molecule ligand that binds to sigma-2 
receptors with high affinity and specificity.21 The tumor-targeting 
efficiency of SV119 has been demonstrated by conjugating 
SV119 with apoptosis-inducing peptides, which resulted in the 
selective killing of tumor cells.22 The present study explores the 
potential of SV119 to mediate the targeted delivery of liposomes 
to multiple tumor cell lines. Liposomes are well-established 
drug carriers for intravenous delivery and several liposomal 
formulations have been approved for clinical applications.23 Our 
results show that the incorporation of a SV119 derivatized PEG-
lipid significantly increases the cellular uptake of liposomes by 
several tumor cell lines, but not by normal cells. In addition, 
DOX-loaded SV119-modified liposomes showed significantly 
higher cytotoxicity compared to unmodified liposomes loaded 
with DOX. These findings suggest that SV119 liposomes may 
have potential for the targeted delivery of anticancer agents to 
tumors that over-express sigma-2 receptors.
Materials and methods
Materials
L-α-phosphatidylcholine (Soy PC), DSPE-PEG(2000)-
OCH
3
, and 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-
N-(lissamine rhodamine B sulfonyl) (ammonium salt) 
(rhodamine-PE) were purchased from Avanti® Polar Lipids, Inc 
(Alabaster, AL). Cholesterol (Chol), doxorubicin hydrochloride, 
FITC-conjugated anti-mouse IgG, 3-[4,5-dimethylthiazol-
2-yl]-2,5-diphenltetrazolium bromide (MTT), and dimethyl 
sulfoxide (DMSO) were purchased from Sigma-Aldrich 
(St Louis, MO, USA). Mouse anti-early endosome antigen 
1 (EEA1) monoclonal antibody was purchased from BD 
Transduction Laboratories. LysoTracker® Green DND-26 was 
purchased from Life Technologies (Invitrogen®; Carlsbad, CA). 
A PD-10 desalting column was purchased from GE Healthcare 
(Little Chalfont, UK). Dulbecco’s phosphate-buffered saline 
(DPBS) was purchased from Life Technologies (Gibco®) and 
t-Boc Amine PEG NHS Ester (TBOC-PEG-NHS, MW 
3500) was purchased from JenKem Technology USA, Inc 
(Allen, TX). All other chemicals and organic solvents were 
purchased from Sigma-Aldrich. 1H nuclear magnetic resonance 
(NMR) spectra were recorded on a Bruker FT 400 MHz. The 
synthesized compounds were also identified by matrix-assisted 
laser desorption/ionization time-of-flight (MALDI-TOF) 
mass spectrometry (Voyager-DE PRO BioSpectrometry 
Workstation; Applied Biosystems®, Life Technologies). The 
mass spectrum was obtained in a linear mode with CHCA as 
the matrix.
Human prostate adenocarcinoma cell line DU-145, 
human lung carcinoma cell line A549, and human breast 
cancer MCF-7 cells were obtained from American Type 
Culture  Collection ([ATCC], Manassas, VA) Rockville, 
MD. BEAS-2B (human bronchial epithelium cell line) was 
generously gifted by Dr Y Peter Di from the University of 
Pittsburgh. The cells were cultured in Dulbecco’s modified 
Eagle’s medium (DMEM; ATCC) and supplemented with 10% 
FBS (Invitrogen®) and 1% penicillin-streptomycin at 37°C in 
a humidified atmosphere of 5% CO
2
 in air. All the reagents 
were obtained from Sigma-Aldrich unless stated otherwise.
Synthesis and chemical characterization 
of SV119-PEG-DOA conjugates  
and intermediates
Figure 1 schematically depicts the synthetic procedure for 
preparing SV119-PEG-DOA. The experimental details are 
delineated below.
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Compound 2
NaH (0.8 g, 60% in oil, 20 mmol) was added to a solution 
of 1 (3.04 g, 10 mmol) and benzyl 2-bromoacetate (2.75 g, 
12 mmol) in THF (50 mL).24 The mixture was stirred over-
night at an ambient temperature. After ether (75 mL) was 
added, the organic solution was quenched with water (30 mL) 
and then washed with a saturated NaCl solution (40 mL), and 
finally, the organic solution was dried over Na
2
SO
4
. After 
the solvent was removed, the crude product was purified 
by flash column chromatography with hexane-ethyl acetate 
(1:1) to obtain compound 2 (4.33 g, 96%) as a pale yellow 
oil. 1H NMR (CDCl
3
) δ 7.98 (s, 1H), 7.37–7.21 (m, 6H), 
6.77 (m, 2H), 5.17 (s, 2H), 5.00 (m, 1H), 3.83 (s, 3H), 3.42 
(m, 2H), 3.27 (m, 2H), 2.33 (m, 2H), 2.30 (s, 3H), 2.13 
(m, 1H), 1.98 (m, 2H), 1.51 (m, 3H), 1.17 (m, 2H). ESI-MS 
m/z 453.5 ([M+H]+).
Compound 3
Chemical name: 2-(3-((2-methoxy-5-methylphenyl)
carbamoyl)-9-aza-bicyclo[3.3.1]nonan-9-yl)acetic acid. Pd/C 
(10%, 500 mg) was added to a solution of 2 (3.62 g, 10 mmol) 
and stirred under atmospheric H
2
 pressure in MeOH (50 mL). 
EtOAc (100 mL) was added after the solvents evaporated 
under a vacuum. The mixture was washed by a saturated 
NaCl solution (40 mL), and finally, the organic solution was 
dried over Na
2
SO
4
. EtOAc was then removed to obtain com-
pound 3 (2.82 g, 100%) as a white solid. 1H NMR (CDCl
3
) 
δ 10.9 (brs, 1H), 7.96 (s, 1H), 7.15 (s, 1H), 6.79 (m, 2H), 
4.96 (m, 1H), 3.83 (s, 3H), 3.32 (m, 2H), 3.04 (m, 2H), 2.35 
(m, 2H), 2.29 (s, 3H), 2.08 (m, 1H), 1.64 (m, 3H), 1.50 
(m, 4H). ESI-MS m/z 363.4 ([M+H]+).
Compound 4
A mixture of Boc-aspartic acid (2.47 g, 10 mmol), oleyl 
amine (8.01 g, 30 mmol), DCC (6.18 g, 30 mmol), and 
DMAP (122 mg, 1 mmol) in anhydrous CH
2
Cl
2
 (60 mL) 
was stirred vigorously at room temperature for 5 hours. 
After the reaction was completed, the mixture was filtered 
and evaporated under reduced pressure, and the residue was 
purified by flash column chromatography (MeOH: CHCl
3
 
1:9) to afford the product (4.40 g, 60%). 1H NMR (CDCl
3
) 
δ 7.93 (m, 1H), 5.37 (m, 4H), 4.17 (m, 1H), 3.24 (m, 4H), 
1.98 (m, 9H), 1.51 (m, 4H), 1.47 (s, 9H), 1.26 (m, 45H), 0.87 
(m, 6H). ESI-MS m/z 719.1 ([M+H]+).
DOA (dioleyl amido aspartic acid)
Trifluoroacetic acid (6 mL) was added to a solution of 4 
(4.4 g, 6 mmol) in anhydrous CH
2
Cl
2
 (6 mL). After stirring 
for 2 hours, the reaction mixture was diluted with CH
2
Cl
2
 
(50 mL) and a saturated aqueous solution of Na
2
CO
3
 (20 mL) 
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Figure 1 Synthesis scheme for SV119-PEG3500-DOA. 
Abbreviations: DOA, dioleyl amido aspartic acid; PEG, polyethylene glycol.
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was added until the gas evolution ceased. The organic layer 
was then separated and washed with brine. Next, the organic 
layers were dried over anhydrous Na
2
SO
4
, filtered, and con-
centrated under reduced pressure. The residue was purified by 
flash column chromatography (MeOH:CHCl
3
 1:9) to afford the 
product (3.70 g, 95%). 1H NMR (CDCl
3
) δ 7.53 (m, 1H), 6.33 
(m, 1H), 5.37 (m, 4H), 3.67 (m, 1H), 3.22 (m, 4H), 1.98 (m, 
9H), 1.50 (m, 4H), 1.26 (m, 45H), 0.87 (m, 6H). ESI-MS m/z 
641.0 ([M+Na]+).
Compound 6
A mixture of Boc-NH
2
-PEG-NHS (350 mg, 0.1 mmol) and 
DOA (63.1 mg, 0.1 mmol) in anhydrous CH
2
Cl
2
 (1 mL) 
was stirred vigorously at room temperature for 2 hours. 
The solution was precipitated in cold diethyl ether and the 
precipitate was washed again by diethyl ether. Anhydrous 
CH
2
Cl
2
 (1 mL) and TFA (1 mL) were added to the precipitate 
and the mixture was stirred for 2 hours. The reaction mixture 
was diluted with CH
2
Cl
2
 (10 mL) and a saturated aqueous 
solution of Na
2
CO
3
 (2 mL) was then added until the gas 
evolution ceased. The organic layer was separated and 
precipitated in cold diethyl ether. The obtained precipitate 
was washed again by diethyl ether.
Compound 7
A mixture of compound 3 (72 mg, 0.2 mmol), PEG-DOA 
(300 mg, 0.1 mmol), DCC ( 41.2 mg, 0.2 mmol), and DMAP 
(12 mg, 0.1 mmol) in anhydrous CH
2
Cl
2
 (1 mL) was stirred 
vigorously at room temperature for 5 hours. The solution 
was precipitated in cold diethyl ether and washed again with 
diethyl ether to obtain compound 7 (245 mg, 73%).
Compound 8
A mixture of compound 1 (304 mg, 1 mmol), succinic 
anhydride (200 mg, 2 mmol), and DMAP (12 mg, 0.1 mmol) 
in anhydrous CH
2
Cl
2
 (1 mL) was stirred vigorously at room 
temperature for 5 hours. The residue was purified by flash 
column chromatography (ethyl acetate) to afford the  product 
(3.70 g, 95%). 1H NMR (CDCl
3
) δ 10.9 (brs, 1H), 7.96 
(s, 1H), 7.15 (s, 1H), 6.79 (m, 2H), 4.96 (m, 1H), 3.83 (s, 3H), 
3.04 (m, 2H), 2.72 (m, 2H), 2.35 (m, 2H), 2.29 (s, 3H), 2.24 
(m, 2H), 2.08 (m, 1H), 1.64 (m, 3H), 1.50 (m, 4H).
Compound 9
A mixture of compound 8 (75 mg, 0.2 mmol), PEG-DOA 
(300 mg, 0.1 mmol), DCC (41.2 mg, 0.2 mmol), and DMAP 
(12 mg, 0.1 mmol) in anhydrous CH
2
Cl
2
 (1 mL) was stirred 
vigorously at room temperature for 5 hours. The solution 
was precipitated in cold diethyl ether and washed again with 
diethyl ether to obtain compound 9 (212 mg, 65%).
Preparation of rhodamine-PE labeled 
liposomes
Rhodamine-PE labeled liposomes with or without SV119 were 
prepared by thin lipid film hydration  followed by probe sonica-
tion. Unmodified liposomes were composed of SPC:Chol:DSPE-
PEG2000:rhodamine-PE in a 7:3:0.5:0.05 molar ratio. A 
chloroform solution of the lipid components was mixed and 
evaporated under a gentle stream of N
2
 followed by vacuum 
for at least 4 hours. The dried lipid films were hydrated with 
DPBS at 4°C overnight with an initial total lipid concentra-
tion of 16 mM. After a brief vortex, the suspension was then 
probe sonicated for 1 hour at a power of 3 watts. The liposomes 
were then passed through a PD-10 desalting column and 
used for fluorescence microscopic and quantitative liposome 
uptake studies. The preparation of the SV119 liposomes fol-
lowed the same procedures, except the DSPE-PEG2000 was 
partially substituted by a DOA-PEG(3500)-SV119 conjugate. 
The size distribution and ζ-potentials of the liposomes were 
monitored with a dynamic light scattering method using the 
Malvern Zetasizer (Nano-ZS; Malvern Instruments Ltd, 
Worcestershire, UK).
Cellular uptake studies
Cells (2 × 104 per well) were seeded onto 48-well plates 
(Corning Inc, Corning, NY) and allowed to attach overnight. 
The complete medium was replaced with the serum-free 
DMEM containing rhodamine-PE labeled liposomes at a 
final total lipid concentration of 800 µM. Unmodified or 
SV119 liposomes were incubated with cells at 37°C for 
1 hour unless otherwise indicated. After incubation, the 
cells were washed three times with ice cold PBS and lysed 
with 200 µl 0.3% Triton X-100 at room temperature for 
0.5 hours. The fluorescence intensity of the cell lysate was 
determined by a PerkinElmer LS 50B luminescence spec-
trometer (Waltham, MA) (λex = 560 nm; λem = 588 nm). The 
results were expressed as arbitrary fluorescence intensity/
mg of protein lysates. All the numbers were subtracted by 
the autofluorescence of the cells incubated in the serum-free 
medium without any formulations. The results are reported 
as the average values of four wells measured from the same 
plate on the same day.
To evaluate the cellular uptake by microscopy, the 
cells were fixed with 4% paraformaldehyde in DPBS at 
4°C for 20 minutes and washed three times by DPBS. 
The fluorescence images were obtained using a Nikon 
fluorescence-phase contrast-optical microscope.
To investigate the effect of free SV119 on the uptake 
of SV119 liposomes, SV119 was conjugated with PEG550 
to increase its water solubility (Figure S1A). The effect of 
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SV119 on the uptake of SV119 liposomes was examined by 
incubating the DU-145 cells with the liposomes in serum-free 
media for 1 hour at 37°C in the presence of SV119-PEG550 
(200 µM) or PEG550 (200 µM), and a fluorescence 
microscopy study was carried out as described above.
Preparation of DOX-loaded liposomes
DOX was encapsulated into unmodified and SV119 liposomes 
using an ammonium sulphate gradient method as previously 
described.25 The components of the blank liposomes were 
similar to the liposomes described in the section titled 
“Preparation of rhodamine-PE labeled liposomes.” The 
percentage of SV119-PEG3500-DOA in the total lipid of 
targeted liposomes was 5 mole%. Instead of DPBS, 250 mM 
ammonium sulfate solution was used to hydrate the lipid 
membrane. DOX (10 mg/mL) dissolved in 5% glucose was 
mixed with the liposomes and incubated at 37°C for 20 minutes. 
The drug/lipid ratio was kept at approximately 100 µg/µmol 
to achieve an encapsulation efficiency greater than 90%.25 
 Nonentrapped DOX was removed by filtration through a 
PD-10 column. After the solubilization of the liposomes 
in 1% (w/v) Triton X-100, the DOX concentration of the 
liposomes was determined by measuring the absorbance at 
480 nm using free DOX solution as a standard.
Cytotoxicity assay
The viability of cells treated by DOX encapsulated in SV119 
liposomes or unmodified liposomes was measured by MTT 
colorimetric assay. DU-145 cells were trypsinized and 
resuspended in serum-free DMEM. The formulations were 
diluted in a serum-free medium and mixed with DU-145 
cell suspension, followed by incubation at 37°C for 1 hour. 
The medium was then removed by centrifugation. The cell 
pellets were resuspended in a complete medium and plated 
on a 96-well plate with a density of 5 × 103 cells per well. The 
cells were cultured at 37°C for another 72 hours followed by 
an MTT assay. Twenty microliters of MTT solution (5 mg/mL 
in PBS) were added to each well and the cells were incubated 
for 4 hours at 37°C. The media were then removed and 150 µL 
DMSO was added to each well. Absorbance at 550/630 nm 
was measured using an Ultramark Microplate Imaging System 
(Bio-Rad Laboratories, Hercules, CA). Six wells were used for 
each sample, and the data were expressed as the percentage of 
viable cells compared to the untreated control cells.
Intracellular localization
DU-145 cells grown to 60%–70% confluence in glass 
bottom dishes (In Vitro Scientific, Sunnyvale, CA) were 
incubated with rhodamine-PE labeled liposomes (with 
3 mole% SV119-PEG-DOA) at 37°C for 3 hours or 16 hours. 
To detect early endosomes, the cells were fixed with 4% 
paraformaldehyde, permeabilized with 0.2% saponin, and 
stained with anti-EEA1 (1:100), followed by FITC-conjugated 
anti-mouse IgG (1:100). To label the lysosomes in live cells, 
LysoTracker Green® (50 nM; Life Technologies) was added 
to the medium 30 minutes before the incubation period 
concluded. The stained cells were rapidly washed with ice-cold 
PBS and observed using an Olympus FV1000 laser scanning 
confocal microscope (Olympus America Inc, Melville, NY).
Statistical analysis
Statistical analysis was conducted using a two-tailed unpaired 
Student’s t-test with the SPSS software (version 11.5; IBM Cor-
poration, Armonk, NY). The data were expressed as mean ± SD 
and differences of P , 0.05 were considered significant.
Results and discussion
Several selective sigma-2 receptor ligands have recently been 
developed and evaluated in vitro and in vivo. For example, 
Mach and Wheeler reported the synthesis of a series of 
N-substituted 9-azabicyclo[3.3.1]nonan-3a-yl phenylcarbam-
ate analogs.26 Several high-affinity sigma-2-selective ligands 
such as SV119 were identified through structure-activity 
relationship (SAR) studies. SV119 has a free amino group 
that is linked to a bridgehead nitrogen atom via a linker group 
of six methylene units. SAR studies suggest that the amino 
group is a preferred substituent for assuring a high affinity 
for σ
2
 receptors and high σ
1
 : σ
2
 selectivity. Nevertheless, 
various SV119 conjugates were synthesized by chemically 
modifying this amino group. For example, coupling SV119 
with a fluorescence molecule via this amino group led to 
the development of a sigma-2-selective probe – SW-120 – 
which was used to effectively assess the sigma-2 receptor 
expression levels in cultured tumor cells.27 In addition, a 
recent study by Spitzer et al showed that coupling SV119 
with a proapoptotic peptide via this amino group similarly 
led to the development of a conjugate that demonstrated 
selective cytotoxicity towards tumor cells that overexpress 
the sigma-2 receptor.28
In order to develop lipid-based nanoparticles that 
incorporate SV119 on the surface, we designed and 
 synthesized a SV119-derivatized PEG-lipid. DOA is a 
double-chain lipid that is synthesized from oleyl amine 
and aspartic acid and can be inserted into the lipid 
bilayer of liposomes. The PEG moiety on liposomes 
provides steric hindrance, which renders the nanopar-
ticles more stable and minimizes nonspecific binding of 
the liposomes on the cell surface.29 After replacing the 
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amine group with a carboxyl group, a SV119-PEG-DOA 
conjugate was synthesized by covalent linkage between 
the SV119 carboxyl group and the PEG terminal amine 
group. Figure 1 illustrates the synthesis scheme of 
SV119-PEG3500-DOA.
Figure 2A shows the NMR spectrum of synthesized 
SV119-PEG3500-DOA. The peaks at 7.2–7.3 ppm are 
attributed to the benzene groups on SV119, the signals at 
5.0–5.2 ppm are attributed to the double bond of DOA, 
the peaks between 3–4 are attributed to the PEG, and the 
signals at 1–2 ppm are attributed to the carbon chain of 
DOA. The molecular weight of the synthesized product 
was determined by MALDI-TOF mass spectrometry. As 
shown in Figure 2B, the spectra exhibited a bell-shaped 
distribution of 44 Da-spaced lines centered at 4754.9 Da 
for SV119-PEG3500-DOA. A comparison between the 
mass spectrum of SV119-PEG3500-DOA (Figure 2B) with 
PEG3500 (Figure S2) and PEG3500-DOA (Figure S3) 
suggests the successful synthesis of the SV119-PEG3500-
DOA conjugate.
The synthesized SV119-PEG-DOA was used to formulate 
targeted liposomes. Liposomes are mainly composed 
of phospholipids and cholesterol. These molecules are 
also components of the cells and, thus, are believed to 
be biocompatible and non-toxic. The present experiment 
demonstrates that all the liposomal formulations have a mean 
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diameter of approximately 90 nm (Table 1), which is optimal 
for penetrating the blood vessels surrounding the tumor and 
subsequent endocytosis by the tumor cells.30
The targeting eff iciency of SV119 liposomes was 
characterized in vitro. Cellular uptake was studied using 
DU-145 cells as target cells. DU-145 is a human prostate 
cancer cell line and these cells are reported to overexpress 
sigma-2 receptors.8 Human bronchial epithelial cells – 
BEAS-2B – were chosen to examine the liposomal uptake 
by normal cells. SV119-PEG3500-DOA was formulated 
into rhodamine-PE labeled liposomes to partially substitute 
PEG2000-DSPE, and the total amount of PEG-conjugated 
lipid in the liposomes was kept at 5 mole%. A longer spacer 
(PEG3500) was used between SV119 and DOA to minimize 
the potential steric hindrance imposed by DSPE-PEG2000 
and to increase the targeting efficiency.31
Figure 3A shows the fluorescence images of the 
DU-145 cells that were treated with rhodamine-PE labeled 
SV119 liposomes. After incubation with SV119 liposomes or 
unmodified liposomes for 1 hour, fluorescence was observed 
on the cell membrane and inside the cells. Increasing 
the amount of SV119 in the liposomes was associated 
with a significant increase in the intensity of rhodamine 
fluorescence. This is in contrast to the unmodified liposomes, 
which showed minimal binding and cellular uptake with the 
DU-145 cells (Figure 3A). Figure 3B shows the quantitative 
measurements of the cell-associated fluorescence 1 hour after 
the DU145 cells were treated with the SV119 liposomes and 
the unmodified liposomes. Consistent with the fluorescence 
imaging studies (Figure 3A), the amount of cell-associated 
fluorescence for the DU-145 cells increased significantly 
as the amount of ligand in the liposomes increased. In 
addition, the binding and uptake of SV119 liposomes was 
competitively blocked by the presence of the SV119-PEG550 
conjugate, but was not inhibited by the same concentration 
of PEG550 (Figure S1B). These results demonstrate that 
the enhanced uptake of SV119 liposomes was mediated 
by SV119.
In order to demonstrate the cell-type specificity of 
the uptake of SV119 liposomes, normal human bronchial 
epithelial cells (BEAS-2B) were tested as a control. 
The results showed little binding and cellular uptake of SV119 
liposomes and unmodified liposomes by the BEAS-2B cells 
(Figure 4A). No difference was found between the SV119 
liposomes and unmodified liposomes in terms of the intensity 
of cell-associated fluorescence (Figure 4B). These observa-
tions suggest that SV119- mediated liposomal uptake is 
specific to tumor cells.
One of the unique features of the sigma-2 receptor is 
its overexpression in multiple types of cancers. Therefore, 
following the demonstration of the specific targeting of 
DU145 cells, we examined the targeting capacity of SV119 
liposomes using several other cancer cell lines, including 
PC-3 (prostate cancer), MCF-7 (breast cancer), A549, and 
201T (lung cancer) cells. Similar to the DU-145 cells, the 
cell-associated fluorescence intensity of the SV119 liposomes 
was much higher than that of the unmodified liposomes in 
all the tumor cell lines tested (Figure 5), which suggests a 
Table 1 Size and zeta potential of SV119 liposomes
SV119-PEG-DOA 0% 1% 3% 5%
Particle size (nm) 90.0 ± 0.2 90.7 ± 0.3 97.6 ± 0.2 89.2 ± 0.6
Zeta potential (mV) −2.0 ± 0.6 −2.4 ± 0.5 −2.2 ± 0.3 −3.1 ± 0.4
Note: Data are the mean ± SD for n = 3.
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Figure 3 Enhanced intracellular uptake of SV119 liposomes by DU-145 cells, 
examined by microscopic study (A) and quantitative analysis (B) (n = 4, mean ± SD). 
In (A), the percentage of SV119-PEG-DOA in the total lipid was 0% (a), 1% (b), 3% (c), 
and 5% (d), respectively. 
Abbreviations: DOA, dioleyl amido aspartic acid; PEG, polyethylene glycol.
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potential for the SV119 liposomes to target multiple types 
of tumors.
Next, we investigated the time course of liposomal 
uptake by the DU-145 cells. As shown in Figure 6, the 
cell-associated fluorescence intensity increased during the 
prolonged incubation within 6 hours for the SV119 liposomes 
and the unmodified liposomes. Note that the cellular 
uptake of the SV119 liposomes was significantly higher 
at each time point compared to the unmodified liposomes. 
This observation further supports our conclusion that the 
incorporation of SV119 significantly enhances the uptake of 
liposomes into tumor cells.
Like many other sigma-2 receptor ligands,26 SV119 has a 
tertiary amine group. Therefore, incorporating SV119 onto 
the surface of liposomes may positively charge the particles, 
which may increase the nonspecific cellular uptake of the 
SV119 liposomes. However, the zeta potential analysis 
showed that the incorporation of up to 5 mol% of lipid-PEG-
derivatized SV119 into the liposomes did not significantly 
alter the surface charge (Table 1), which excluded the 
possibility that the enhanced uptake was mediated by a 
non-specific charge-charge interaction. Furthermore, to 
minimize the protonation of the amine nitrogen, a modified 
SV119 (mSV119) was synthesized by introducing an adjacent 
carbonyl group, and the mSV119 was similarly conjugated 
with PEG3500-DOA for incorporation into the liposomes 
(Figure 7A). This modification did not affect the targeting 
efficiency of the ligand (Figure 7B). This result may shed 
new light on the structure-activity relationship, which may 
aid in the design of new sigma-2 receptor ligands.
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Figure 4 Cellular uptake of liposomes by BEAS-2B cells. Microscopic images (A), 
and quantitative analysis (B) (n = 4, mean ± SD). The percentage of SV119-PEG-
DOA in the total lipid was 0% (a), or 3% (b). 
Abbreviations: DOA, dioleyl amido aspartic acid; PEG, polyethylene glycol.
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Figure 5 Uptake of SV119 liposomes by MCF-7 (A), PC-3 (B), 201T (C), and 
A549 cells (D) (n = 4, mean ± SD). 
Abbreviations: DOA, dioleyl amido aspartic acid; PEG, polyethylene glycol.
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Figure 6 Time-course of cellular uptake for SV119 liposomes. 
Notes: Rhodamine-PE labeled liposomes with 0% or 3% SV119-PEG-DOA were 
incubated with DU-145 cells for an indicated period at 37°C. (n = 4, mean ± SD). 
Abbreviations: DOA, dioleyl amido aspartic acid; PEG, polyethylene glycol.
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After demonstrating the efficiency and specificity of 
SV119 in mediating the uptake of liposomes by tumor 
cells, we investigated the utility of the SV119 liposomes 
for the targeted delivery of anticancer agents. We chose 
DOX because it is a chemotherapeutic drug widely used 
in clinical therapy. The DU-145 cells were pre-treated with 
DOX-loaded SV119 liposomes (SV119-L[D]), DOX-loaded 
unmodified liposomes (L[D]) and free DOX for 1 hour. The 
cells were then cultured for an additional 72 hours before 
the MTT assay was conducted. The results show that the 
cytotoxic effects of all the treatments were dose-dependent 
at concentrations of 0.2∼10 µg/mL (Figure 8). At each 
of the indicated concentrations, the viability of the cells 
treated with L[D] showed enhancements of 1.5–3-fold, 
compared with that of the free DOX, which suggests that 
the cells were protected by the encapsulation of the drug 
in the liposomes. In addition, SV119-L[D] exhibited 
an ∼2-fold higher cytotoxicity to the DU-145 cells than 
L[D] (Figure 8), which suggests improved efficacy of 
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Figure 7 Uptake of liposomes decorated with modified SV119 (mSV119) by DU-
145 cells. Scheme of synthesis (A) and microscopic images (B) (n = 4, mean ± SD). 
In (B), the percentage of mSV119-PEG-DOA in the total lipid was 0% (a), 1% (b), 
3% (c), and 5% (d), respectively. 
Abbreviations: DOA, dioleyl amido aspartic acid; PEG, polyethylene glycol.
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Figure 8 Cytotoxic effect of free and liposomal DOX on DU-145 prostate cancer 
cells. Cells were treated with free DOX, DOX-loaded SV119 liposomes or DOX-
loaded unmodified liposomes with DOX concentrations of 0.2, 1, or 10 µg/mL. 
Cytotoxicity was assessed by MTT assay. Cells receiving no treatment were defined 
as the maximal cell viability. Values presented are the mean ± SD of six replicates. 
Note: *P , 0.05 compared to the control treatments with unmodified liposomes. 
Abbreviations: DOX, doxorubicin; L[D], DOX-loaded unmodified liposomes.
the SV119-modified liposomes versus the unmodified 
liposomes for delivering DOX to the tumor cells. The 
increased cytotoxicity of SV119-L[D] is consistent with 
the enhanced uptake of the SV119 liposomes, as shown in 
Figure 3. This demonstrates that the SV119 liposome can 
potentially be used a carrier for the targeted delivery of 
chemotherapeutics to tumor cells.
Despite the enhanced cellular uptake of the SV119 
liposomes, it is crucial to understand the intracellular fate of 
the liposomes in order to maximize the bioavailability of the 
loaded drug. Nanoparticles internalized via the endocytosis 
pathway are often sequestered in endosomes and lysosomes, 
which represent an intracellular barrier that limits the 
accessibility of encapsulated agents to reach their molecular 
targets. In this study, confocal microscopy was used to examine 
the intracellular localization of rhodamine-PE labeled SV119 
liposomes in DU-145 cells. After 3 hours of incubation, 
the liposomes showed a peri-nuclei punctuated distribution 
that is substantially co-localized with early endosomes 
(Figure 9A–C). After 13 hours of additional incubation, the 
liposomes were largely accumulated in the lysosomes, as 
evidenced by the colocalization with the lysosome markers 
(LysoTracker®; Figure 9D–F). These observations are 
consistent with the internalization via the endocytosis pathway. 
Future studies are warranted to improve the formulation and 
to achieve more efficient release from the endosomes and 
lysosomes.
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Conclusion
We have demonstrated the successful synthesis of the 
functional lipid, SV119-PEG-DOA, as well as its incorporation 
into a liposome formulation for targeted delivery to cancer 
cells. As compared with unmodified liposomes, the SV119 
liposomes demonstrated enhanced uptake in multiple types 
of tumor cell lines including DU-145, MCF-7, PC-3, 201T, 
and A549 cells. In addition, this enhanced uptake was 
shown to be dependent on ligand density and incubation 
time, and the uptake of SV119 liposomes was dramatically 
inhibited by the presence of free SV119. In contrast, the 
enhanced uptake of SV119 liposomes was not observed 
in BEAS-2B normal cells, which suggests that enhanced 
uptake is tumor cell-specific. Furthermore, results of the 
MTT assay suggest that incorporating SV119 onto the 
surface of liposomes significantly enhances the delivery 
and cytotoxicity of liposomal DOX in vitro. At the time 
of writing this manuscript, Xia and colleagues reported 
that SV119 mediated the selective delivery of SV119-gold 
nanocage conjugates to tumor cells.32 Collectively, these data 
suggest that SV119-conjugated nanoparticles may represent 
a promising delivery system for the targeted delivery of 
anticancer therapeutics to tumor cells.
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Supplementary materials
Synthesis of SV119-PEG550
SV-119 succinate
A solution of SV-119 (2.0 g, 5 mmol) in CH
2
Cl
2
 (20 mL) was 
treated with DMAP (1.2 g, 10 mmol) and succinic anhydride 
(1 g, 10 mmol). The reaction was reflexed and stirred over-
night. After the reaction was completed, the crude product 
was purified by flash chromatography with silica gel (EtOAc: 
PE, 3:1) to obtain SV-119 succinate.
SV119-PEG550
A solution of SV-119 succinate (2.5 g, 5 mmol) in CH
2
Cl
2
 
(10 mL) was treated with DCC (0.82 g, 4 mmol), DMAP 
(0.12 g, 1 mmol), and MeO-PEG550-OH (2 g, 3.6 mmol). 
The reaction was stirred at room temperature overnight. After 
the reaction was completed, 100 mL of Et
2
O was added and the 
mixture was filtered to afford the crude product. The crude 
product was purified by flash  chromatography with silica 
gel (MeOH: CH
2
Cl
2
, 1:10) to afford pure SV119-PEG550. 
1H NMR δ 7.14 (s, 1H), 6.73–6.80 (m, 2H), 5.14 (m, 1H), 
3.85 (s, 3H), 3.60–3.70 (m, 50H), 3.36 (s, 3H), 3.05–3.10 
(m, 2H), 2.66–2.71 (m, 2H), 2.55–2.60 (m, 2H), 2.40–2.50 
(m, 6H), 2.30 (s, 3H), 2.08–2.24 (m, 1H), 1.82–1.94 (m, 2H), 
1.20–1.55 (m, 14H).
Method for testing the effect of SV119  
on the uptake of SV119-liposomes
DU-145 cells were treated with SV119-liposomes (with 
3% SV119-PEG-DOA) in a serum-free Dulbecco’s modi-
fied Eagle’s medium (DMEM; American Type Culture 
Collection [ATCC], Manassas, VA) for 1 hour in the 
presence of PEG550 (200 µM) or SV119-PEG550 (200 
µM). The cells were treated with unmodified liposomes or 
SV119-liposomes alone as control groups. Fluorescence 
images were taken, as described in the section titled “Cel-
lular uptake studies.”
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Figure S1 Scheme of synthesis for SV119-PEG550 (A) and effect of SV119 on the uptake of SV119-liposomes by DU-145 cells (B). 
Abbreviation: PEG, polyethylene glycol.
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Figure S2 MALDI-TOF mass spectrometry of PEG3500. 
Abbreviations: MALDI-TOF, matrix-assisted laser desorption/ionisation-time of flight; PEG, polyethylene glycol.
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Figure S3 MALDI-TOF mass spectrometry of PEG3500-DOA. 
Abbreviations: DOA, dioleyl amido aspartic acid; MALDI-TOF, matrix-assisted laser desorption/ionisation-time of flight; PEG, polyethylene glycol.
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